The European Ccommission approves Avzivi ,a biosimilar referencing bevacizumab
The European Medicines Agency (EMA) has approved Avzivi (BAT 1706), a biosimilar referencing bevacizumab (Avastin), according to an announcement from Bio-Thera Solutions
Avzivi is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.
“The EMA approval of Avzivi is another significant accomplishment for Bio-Thera as it marks Bio-Thera’s second EMA-approved product” Shengfeng Li, chief executive officer at Bio-Thera Solutions, stated in a news release. “As our biosimilar pipeline continues to mature, we intend to seek more biosimilar approvals, expanding patient access to important therapies.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins